Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:ENZ
Previous Symbol
CUSIPN/A
Phone212-583-0100
Debt
Debt-to-Equity RatioN/A
Current Ratio4.15
Quick Ratio3.76
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$104.71 million
Price / Sales1.32
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.60 per share
Price / Book1.83
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-10,320,000.00
Net Margins-15.93%
Return on Equity-20.25%
Return on Assets-16.37%
Miscellaneous
Employees503
Outstanding Shares47,190,000
Market Cap$139.22 million
OptionableOptionable
